
ResMed (RMD) Stock Forecast & Price Target
ResMed (RMD) Analyst Ratings
Bulls say
ResMed is a strong investment opportunity due to its positive revenue outlook supported by an ageing population and increasing prevalence of obesity. The company's focus on digital health and clinical data sets it apart from its competitors, and its recent acquisition of MatrixCare will likely further enhance its offerings. Risks to the company include potential competition and potential disruptions in the sleep market from GLP-1 drugs. EPS increases and strong performances in key areas further strengthen the positive outlook.
Bears say
ResMed is facing uncertainty in its growth opportunities due to the impact on the diagnosis and treatment of sleep apnea from GLP-1 drugs, and the recent sale of its MatrixCare business for $490m suggests a lack of confidence in future growth prospects from management. The company has a highly defensive revenue stream, but potential risks include increased competition, lack of technological innovation, and updates on GLP-1 trials. Overall, the uncertainty surrounding GLP-1 impacts and recent developments suggest a cautious outlook for ResMed's stock.
This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.
ResMed (RMD) Analyst Forecast & Price Prediction
Start investing in ResMed (RMD)
Order type
Buy in
Order amount
Est. shares
0 shares